Ann: Capital Raising Presentation, page-78

A big toe might be amputated for critical limb (well a toe isn't a limb - but there is vascularisation - blood vessels) ischemia perhaps rather than a through the skin wound - I don't know - its just a possibility.
It's a possibility, but most likely it was an amputation from a diabetic wound given the extraordinary number that occur and the incidence rate amongst diabetics.

I think you did use the word 'significant'. But what we actually need is statistical significance. And from memory I think 6 samples is about as few as is possible to do that with - students t tests and the like. But I'm willing to be corrected.
You can get a p value of <0.05 depending on the sensitivity of SOC population data and what you think the other two CYP patients have experienced.

I looked for CYP and MSB in a recent list of stocks that Commsec was willing to grant margin loans against using the shares themselves - neither were there.

It is probably for the best that CBA is not loaning money against cash-burning clinical-stage biotech companies. I don't think Cynata was ever eligible for this - usually they have to be ASX300 - there are some exceptions of course.